Abstract
Background: Previous studies have suggested that niacin may have antiplatelet properties, however the effects of niacin on the platelet activity are not well defined.
Objective: The purpose of this trial was to investigate whether the oral administration of niacin inhibits platelet aggregation.
Method: This study was run in three segments measuring the inhibitory effect of niacin: 1) 3 mmol/L niacin in vitro, 2) one hour after 1-gram sustained-release (SR) niacin administration, 3) twelve hours after 2-gram SR niacin administration. Platelet aggregation was measured using the VerifyNow-Aspirin and whole blood impedance aggregometry.
Results: Preincubation with niacin resulted in a significant inhibition of platelet aggregation. Significant inhibition of platelet aggregation was found one hour following the oral administration of 1 gram of SR niacin while the oral administration of a 2 gram dose of SR niacin did not produce significant platelet inhibition when platelet aggregation was measured 12 hours after the dose.
Conclusion: Niacin has a small, direct effect on platelet aggregation. Niacin platelet inhibition is transient and may dissipate as it is converted into metabolites. The clinical significance is unknown.
Keywords: Niacin, pharmacology, pharmacodynamics, platelet aggregation.
Current Clinical Pharmacology
Title:Oral Administration of Sustained Release Niacin Inhibits Platelet Aggregation
Volume: 11 Issue: 1
Author(s): Nicholas B. Norgard, Nicholas R. Bacon and Matthew Agosti
Affiliation:
Keywords: Niacin, pharmacology, pharmacodynamics, platelet aggregation.
Abstract: Background: Previous studies have suggested that niacin may have antiplatelet properties, however the effects of niacin on the platelet activity are not well defined.
Objective: The purpose of this trial was to investigate whether the oral administration of niacin inhibits platelet aggregation.
Method: This study was run in three segments measuring the inhibitory effect of niacin: 1) 3 mmol/L niacin in vitro, 2) one hour after 1-gram sustained-release (SR) niacin administration, 3) twelve hours after 2-gram SR niacin administration. Platelet aggregation was measured using the VerifyNow-Aspirin and whole blood impedance aggregometry.
Results: Preincubation with niacin resulted in a significant inhibition of platelet aggregation. Significant inhibition of platelet aggregation was found one hour following the oral administration of 1 gram of SR niacin while the oral administration of a 2 gram dose of SR niacin did not produce significant platelet inhibition when platelet aggregation was measured 12 hours after the dose.
Conclusion: Niacin has a small, direct effect on platelet aggregation. Niacin platelet inhibition is transient and may dissipate as it is converted into metabolites. The clinical significance is unknown.
Export Options
About this article
Cite this article as:
Norgard B. Nicholas, Bacon R. Nicholas and Agosti Matthew, Oral Administration of Sustained Release Niacin Inhibits Platelet Aggregation, Current Clinical Pharmacology 2016; 11 (1) . https://dx.doi.org/10.2174/1574884711666151214104315
DOI https://dx.doi.org/10.2174/1574884711666151214104315 |
Print ISSN 1574-8847 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3938 |
Related Articles
-
Members of CRF Family and their Receptors: From Past to Future
Current Medicinal Chemistry Emerging Therapy Options in Heparin-Induced Thrombocytopenia
Cardiovascular & Hematological Agents in Medicinal Chemistry The pH of Wound Fluid in Diabetic Foot Ulcers- the Way Forward in Detecting Clinical Infection?
Current Diabetes Reviews GPER/GPR30 and Regulation of Vascular Tone and Blood Pressure
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Microalgal Fatty Acids and Their Implication in Health and Disease
Mini-Reviews in Medicinal Chemistry Oxidative Stress and Antioxidants in Hypertension–A Current Review
Current Hypertension Reviews Alcohol and the Cardiovascular System: A Double-Edged Sword
Current Pharmaceutical Design Omega-3 Fatty Acids in the Management of Epilepsy
Current Topics in Medicinal Chemistry Withdrawal Notice: Therapeutic Options for Treatment of COVID-19: A Review from Repurposed Drugs to New Drug Targets
Current Drug Targets Lessons from the REACH Registry in Europe
Current Vascular Pharmacology The Dialogue Between Endothelial Cells and Monocytes/Macrophages in Vascular Syndromes
Current Pharmaceutical Design Inflammatory Biomarkers in Chronic Kidney Disease: A Review
Recent Patents on Biomarkers Protective Role of Diabetes Mellitus on Abdominal Aortic Aneurysm Pathogenesis: Myth or Reality?
Current Vascular Pharmacology Coarse Classification to Region-Scalable Refining for White Matter Lesions Segmentation in Multi-Channel MRI
CNS & Neurological Disorders - Drug Targets A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes
Current Pharmaceutical Design Issues and Progress in Isolation of Susceptibility Genes of Essential Hypertension
Current Hypertension Reviews Parental Hypertension and Cardiovascular Reactivity in Young Adults
Vascular Disease Prevention (Discontinued) Is Combination Therapy of Atosiban and Nifedipine More Effective in Preterm Labor than Each Drug Alone? A Prospective Study
Current Women`s Health Reviews The Therapeutic Role of Taurine in Ischaemia-Reperfusion Injury
Current Pharmaceutical Design Beta-Blockers use for Hypertension in the Elderly
Cardiovascular & Hematological Agents in Medicinal Chemistry